Lyell Immunopharma presented initial clinical data from its Phase 1-2 study of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell therapy, at the 66th American Society of Hematology (ASH) Annual Meeting. The study investigates IMPT-314 in patients with relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma.
IMPT-314: Dual-Targeting CAR T-Cell Therapy
IMPT-314 is an autologous bispecific CD19/CD20 chimeric antigen receptor (CAR) T-cell product candidate. It is designed to target both CD19 and CD20 proteins found on B-cells, potentially offering a more robust approach to treating B-cell lymphomas. The therapy incorporates enriched naive and central memory T cells to enhance durability and efficacy.
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to IMPT-314 for the treatment of relapsed/refractory aggressive B-cell lymphoma. This designation is intended to expedite the development and review of drugs that treat serious conditions and fill unmet medical needs.
Clinical Data Presented at ASH
The presentation at ASH featured data from the Phase 1-2 clinical trial. Sarah M. Larson, M.D., Associate Professor at the David Geffen School of Medicine at UCLA, presented the findings. The study aims to evaluate the safety and efficacy of IMPT-314 in patients with large B-cell lymphoma (LBCL).
Lyell is a clinical-stage company focused on developing next-generation CAR T-cell therapies for both solid tumors and hematologic malignancies. Their technology is designed to generate T cells that resist exhaustion and maintain stemness, potentially leading to durable tumor cytotoxicity and long-lasting clinical responses.
